 MINNEAPOLIS--BUSINESS WIRE--DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biopharmaceutical Company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food Drug Administration FDA has accepted the Companys Investigational New Drug IND application. The Company plans to proceed with a pivotal Phase 23 study of DM199 recombinant human tissue kallikrein-1or KLK1 for the treatment of patients with Acute 